IORG Daily Chart ~ Continuation to the Upside

New Post Public Reply Private Reply Replies (0) Message Board
Big Tuna
IORG Daily Chart ~ Continuation to the Upside Underway

First of all, on a fundamental basis only, if you haven't yet reviewed the IORG website, get to work:

http://intreorg.com

On a technical basis, IORG is trading beautifully. Last week, the stock price finished at .50. For the week, the stock was up approx 30%. I initially shared IORG when it was quoted .08 x .15 in early to mid November. There was very little to be had at those levels, though. The stock has since appreciated to the closing high of .65 set on Thursday and again on Friday. While the candles traded outside the upper bollie into Thursday's close, the bollie was at .57. Friday's trading saw some sideways movement from .625 to .65, while the bollie band appreciated to .629. So, although the Friday's candle was trading outside the upper bollie, it's only by a small amount. If it were .05-.10 outside the bands, that would cause some short term, trading concern for me. This issue, though, lies in if one were to sell 25k-50k+, can one re-enter with that size on any pullback? Hard to say. But with a float around 5.4MM and only trading approx 25,000 per day over the last three months, it would be a risky endeavor in my opinion. Keep in mind, the average trading volume has primarily been on the upside. It would suck if one were to sell any size while those accumulating absorbed one's shares, leaving even a tighter held float than it already is. GLTA

1320869287_IORG.png
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Investigation Alerts for Spyre Therapeutics Investors Amid Concerns

Updated Category News Views 143

Investigation of Claims for Spyre Therapeutics Investors Pomerantz LLP is currently investigating claims on behalf of investors of Spyre Therapeutics, Inc. (NASDAQ: SYRE). The firm seeks to understand whether Spyre and its executives have potentially engaged in any unlawful business practices, specifically concerning securities fraud. Understanding the Securities Concerns...

Continue Reading
Natixis CIB's Pioneering Project Financing for Infrastructure

Updated Category News Views 126

Natixis CIB's Role in Groundbreaking Project Financing Natixis Corporate & Investment Banking (Natixis CIB) has taken a significant step in enhancing infrastructure development by serving as Joint Bookrunner and Joint Lead Arranger for a remarkable $281 million project financing. This financing initiative will support Ruta del Este, a concessionaire formed by ISA Vías to...

Continue Reading
Finch Therapeutics Moves to Delist from Nasdaq Amid Challenges

Updated Category News Views 177

Finch Therapeutics Plans Delisting from Nasdaq Finch Therapeutics Group, Inc. (Nasdaq: FNCH) has recently announced its decision to delist from The Nasdaq Stock Market, LLC. This move is part of a broader strategy aimed at navigating current market challenges and optimizing operational efficiency. The company is a leader in microbiome technology, boasting a strong...

Continue Reading
ModivCare: Exploring Recent Developments and Stockholder Rights

Updated Category News Views 269

Investigating the Latest Events Surrounding ModivCare Recent events surrounding ModivCare, Inc. have drawn considerable attention from the investor community and law firms alike. This scrutiny comes after a class action lawsuit from long-term shareholders, alleging the company's management may have misled investors about its ability to manage its financial health during a...

Continue Reading
Investors in Avantor, Inc. Urged to Act Before Key Deadline

Updated Category News Views 157

A Call to Action for Avantor, Inc. Investors Investors in Avantor, Inc. should take heed of an essential notification regarding a securities class action. As a market participant interested in Avantor, Inc. (NYSE: AVTR), your involvement could be crucial. This class action centers around stock purchases made during a specific timeframe that is intended to hold the company...

Continue Reading